Altimmune (ALT)
(Delayed Data from NSDQ)
$7.51 USD
+0.49 (6.98%)
Updated May 31, 2024 04:00 PM ET
After-Market: $7.52 +0.01 (0.13%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Brokerage Reports
0 items in cart
Altimmune, Inc. [ALT]
Reports for Purchase
Showing records 21 - 40 ( 75 total )
Company: Altimmune, Inc.
Industry: Medical - Drugs
Compelling Update of Potential Best-in-Class Weight Loss Treatment Pemvidutide at EASL
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Altimmune, Inc.
Industry: Medical - Drugs
1Q22 Results; Lead Candidate Pemvidutide Phase 2 Data Expected in 4Q22; Extends Cash Runway to 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Altimmune, Inc.
Industry: Medical - Drugs
HCW "At Home" Recap; Reiterate Buy Ahead of Catalysts on Potential Blockbuster Obesity and NASH Program
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Altimmune, Inc.
Industry: Medical - Drugs
Company: Altimmune, Inc.
Industry: Medical - Drugs
We cordially invite you to attend a fireside chat
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Altimmune, Inc.
Industry: Medical - Drugs
Reiterate Buy Ahead of Anticipated Compelling Obesity and NAFLD Data Expected in 2022 on Lead Compound Pemvidutide
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Altimmune, Inc.
Industry: Medical - Drugs
Pemvidutide Positive Phase 1 12-Week Results Pave Way for Broad Program Expansion in Obesity and NASH; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Altimmune, Inc.
Industry: Medical - Drugs
Company: Altimmune, Inc.
Industry: Medical - Drugs
Expansion of Underappreciated ALT-801 Program in Obesity and NASH Bodes Well for Shareholders; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Altimmune, Inc.
Industry: Medical - Drugs
AdCOVID Intranasal Vaccine Data Disappoints; Focus Shifts to Liver Disease, Obesity; Price Target to $25; Maintain Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Altimmune, Inc.
Industry: Medical - Drugs
ALT-801 Generates Initial Positive Data in Obesity, a Second Potential Blockbuster Indication; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Altimmune, Inc.
Industry: Medical - Drugs
Company: Altimmune, Inc.
Industry: Medical - Drugs
Final Program for Our Fourth Annual Virtual NASH Investor Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Altimmune, Inc.
Industry: Medical - Drugs
We are updating coverage of our Healthcare sector to better allocate our research resources in
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Altimmune, Inc.
Industry: Medical - Drugs
Company: Altimmune, Inc.
Industry: Medical - Drugs
Coronavirus Vol. 52: Nasal Cavity Is a Prime Target for SARS-CoV-2
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y